Leading Decision Makers Provide a Briefing On the New Administration's Initiatives On Biodefense Vaccines and Therapeutics.
Don't Miss the Two Pre-Conference Events:
The Regulatory Symposium and Technical Symposium
The Biodefense Vaccines and Therapeutics conference is the ideal venue to learn the latest and most detailed information on current countermeasure research, development, and procurement programs; as well as interact face-to-face with high-level government representatives tasked with building the country’s biodefense and pandemic influenza capacity. The government’s senior biodefense and pandemic experts will be on hand to explain:
- Priorities and directions of various federal agencies
- Federal funding availability at various stages of development and procurement
- Processes and procedures for funding access
- Options for transitioning products from development to procurement
- Government plans for supporting infrastructure investments
In addition to government officials, representatives from leading biotechnology and pharmaceutical firms will provide their experiences, perspectives and feedback on:
- Government programs currently accelerating development of countermeasures
- Initiatives to strengthen government and industry collaborations
- The potential to build up a profitable and viable biodefense and pandemic influenza business sector
The Biodefense Vaccine and Therapeutics conference has established itself as the premier venue for key government representatives to share their strategic plans and to provide thorough information on the roles of industry, researchers, universities and the public health community in the government’s biodefense and pandemic influenza efforts. In short, this conference provides the crucial information needed to make informed decisions about participation and involvement in this arena, as well as an opportunity to provide feedback and help shape the government’s strategic plans for expanding participation in federal programs.
Featured Speakers
Steve Adams, MPH, Deputy Director, DSNS, CCTPER, CDC
Diane Berry, Ph.D., Chief Scientist, Office of Health Affairs, DHS
Albert Churilla, Ph.D., J.D., Chief, Medical S&T, Chem/Bio Technologies Directorate, DTRA
Darrell Galloway, Ph.D., Director, Chemical/Biological Technologies, Research & Development Enterprise, DTRA
Gerald Kovacs, Ph.D., Director, Division of CBRN Countermeasures, BARDA, OASPR, DHHS
Michael Kurilla, M.D., Ph.D., Director, Office of BioDefense Research Affairs and Associate Director for BioDefense Product Development, NIAID
Monique Mansoura, Ph.D., Director for Policy, Planning and Requirements, BARDA, OASPR, DHHS
Robin Robinson, Ph.D., Director, BARDA, OASPR, DHHS
Col. David Williams, Joint Project Manager, Chemical Biological Medical Systems, JPEO-CBD